KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Short-Term Debt issuances (2016 - 2026)

Eli Lilly filings provide 17 years of Short-Term Debt issuances readings, the most recent being $1.8 billion for Q1 2026.

  • On a quarterly basis, Short-Term Debt issuances rose 196.0% to $1.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$714.0 million, a 147.48% decrease, with the full-year FY2025 number at -$4.3 billion, down 134.23% from a year prior.
  • Short-Term Debt issuances hit $1.8 billion in Q1 2026 for Eli Lilly, up from -$400000.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $4.6 billion in Q4 2023 to a low of -$5.2 billion in Q1 2024.
  • Median Short-Term Debt issuances over the past 5 years was $249.6 million (2022), compared with a mean of $110.9 million.
  • Biggest five-year swings in Short-Term Debt issuances: tumbled 9632.0% in 2022 and later skyrocketed 1988.2% in 2023.
  • Eli Lilly's Short-Term Debt issuances stood at -$243.3 million in 2022, then skyrocketed by 1988.2% to $4.6 billion in 2023, then plummeted by 33.78% to $3.0 billion in 2024, then tumbled by 100.01% to -$400000.0 in 2025, then surged by 443850.0% to $1.8 billion in 2026.
  • The last three reported values for Short-Term Debt issuances were $1.8 billion (Q1 2026), -$400000.0 (Q4 2025), and -$4.1 billion (Q3 2025) per Business Quant data.